"ProMIS (@ProMISinc) (#TSX: $PMN | #OTCQB: $ARFXF) PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies [https://t.co/aIpxf3qPbX]#investing #stocks #stockmarket #trading #investors #news #business #investments #biotech #pharma #alzheimersdisease"Read full news